The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Chronic spontaneous urticaria is chronic inflammatory skin disease driven in part by type 2 inflammation, which causes sudden ...

They achieved this by developing sucralfate microneedles (SUC-MN) to deliver an important immunomodulatory protein, interleukin-4 (IL-4), to stimulate the production of growth factors in diabetic ...

The FDA approved dupilumab (Dupixent) for chronic spontaneous urticaria (CSU) in patients 12 years and older, the first new ...

They achieved this by developing sucralfate microneedles (SUC-MN) to deliver an important immunomodulatory protein, interleukin-4 (IL-4), to stimulate the production of growth factors in diabetic ...

The researchers found 1.4 serious infections per 100 person-years ... Researchers conclude that biologics targeting interleukin pathways may be safer alternatives for older adults with psoriatic ...